Iteos Therapeutics (ITOS) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Key learnings from recent clinical trials

• Statistical design and quality of study components are critical for success in immuno-oncology trials, as seen in the differences between CITYSCAPE and SKYSCRAPER-01 studies.

• Using pembrolizumab as a comparator is considered more relevant than atezolizumab for future studies.

• Six to ten months improvement in overall survival is seen as a significant and achievable target for TIGIT combinations in high PD-L1 non-small cell lung cancer.

• Dose optimization, driven by regulatory guidance, led to the selection of 400 mg as the optimal balance between efficacy and tolerability for phase III.

• Physician management and communication are expected to help manage discontinuation rates due to immune-related toxicities.

Clinical development and trial strategy

• High PD-L1 patients predominantly receive PD-1 monotherapy, supporting the rationale for chemo-free regimens.

• Enrollment for studies using pembrolizumab or dostarlimab has not faced significant challenges across geographies, though competition in the U.S. is high.

• There is strong physician interest in participating in chemo-free regimen trials, with ongoing phase II and phase III studies.

Expansion into new indications and combinations

• Aggressive development in head and neck cancer is based on biological rationale and unmet need, with significant data readouts expected next year.

• Decisions to advance to phase III in head and neck will be data-driven, considering evolving benchmarks and competitive bispecifics.

• Exploration of TIGIT triplets and the CD226 axis, including CD96 and PVRIG, is ongoing, with first clinical data expected next year.